<DOC>
	<DOCNO>NCT02257359</DOCNO>
	<brief_summary>Epelsiban potent selective oxytocin receptor antagonist development enhance implantation rate in-vitro fertilization ( IVF ) . This study non-randomized , open label study design assess safety , tolerability pharmacokinetics additional repeat dos epelsiban healthy female , first dose experience great 200 milligram ( mg ) single dose compound . Data study inform selection dose epelsiban use future clinical study . This study compose 3 period : Screening , Treatment , Follow-up . The total duration subject involve study 6 week . At least 2 cohort subject enrol study cohort conduct sequentially . Additional cohort enrol determined necessary . A sufficient number subject screen study obtain approximately 6 evaluable subject per cohort .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics Epelsiban Healthy Female Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Diketopiperazines</mesh_term>
	<criteria>Females 18 55 year age inclusive , time consent . Healthy determine Investigator medically qualify designee base medical evaluation include medical history , review medication previously use , physical examination , laboratory test ECG . Body mass index ( BMI ) within range 1835 kilogram per square meter ( kg/m^2 ) ( inclusive ) . Female subject eligible participate pregnant ( confirm negative serum human chorionic gonadotropin [ hCG ] test ) , lactate , least one follow condition applies : Nonreproductive potential postmenopausal . Exclusion Criteria Alanine Transferase ( ALT ) bilirubin &gt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Corrected QT ( QTc ) &gt; 450 millisecond ( msec ) . History regular alcohol consumption within 3 month dose Day 1 define : average weekly intake &gt; 7 drink female . One drink equivalent 12 gram alcohol : 12 ounce ( 360 milliliter [ mL ] ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion Investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose Study Treatment . For potent immunosuppressive agent , subject presence hepatitis B core antibody ( HBcAb ) also exclude . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus antibody . Where participation study would result donation blood blood product excess 500 mL within 3 month . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Epelsiban</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy Female Volunteers</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Oxytocin</keyword>
</DOC>